Tagged: Journal of Cardiac Failure
Type 2 diabetes (T2D) is an established risk factor for ischemic cardiovascular disease (CVD) and heart failure (HF).(1) The risks of ischemic CVD and HF are increased with albuminuria and/or impaired kidney function. Although in recent decades cardiovascular outcomes have improved for adults with or without T2D, reducing the burden associated with HF by treating classical cardiovascular risk factors has proven to be difficult and thus remains a major public health priority.(2) Accordingly, the introduction of sodium-glucose cotransporter (SGLT) 2 inhibitors offers promise to mitigate cardiorenal disease in people with or without T2D.
The wild type transthyretin amyloid cardiomyopathy (wtATTR) is associated with significant morbidity and mortality with variable median survival around 2-6 years.(1) Recently, Tafamidis received FDA approval for use in ATTR-CM patients after ATTR-ACT randomized controlled trial showing improvement in quality of life and mortality benefit.(2)
Pericardial adipose tissue (PAT) is associated with adverse cardiovascular outcomes in those with and without established heart failure (HF). However, it is not known whether PAT is associated with adverse outcomes in patients with end-stage HF undergoing LVAD. This study aimed to evaluate the associations between PAT and LVAD-associated outcomes.
I recently took care of a young woman in her thirties in my fellows’ clinic with a newly diagnosed non-ischemic cardiomyopathy with mild dilation and a left ventricular ejection fraction (LVEF) of 20%. She had presented in the middle of the COVID-19 pandemic with decompensated heart failure of unclear etiology. She had three young and healthy children at home, with her last pregnancy a few years earlier. She tolerated her prior pregnancies well with the exception of gestational hypertension that evolved into chronic hypertension.
Right heart dysfunction (RHD) parameters, such as pulmonary hypertension (PH), right ventricular dysfunction (RVD), or tricuspid regurgitation (TR), are highly prevalent and increasingly important in heart failure (HF), especially in patients with HF with preserved ejection fraction (HFpEF), in whom PH-RVD has emerged as a specific clinical phenotype. 1-5 Overall, parameters of RHD have been associated withadverse clinical outcomes.3-9 Our group recently proposed an echocardiographic-derived staging system of RHD for risk stratification in HFpEF.